OccamPoint® Webinar Presents
Sponsored By
Featured Presentation
A Biostatistician's Perspective on Challenges, Innovation, and Future Direction
Data Safety Monitoring Boards (DSMBs) play a critical role in safeguarding participant safety and ensuring the integrity of clinical trials. However, the evolving landscape of clinical research, increasing data complexity, and the AI-driven tools present new opportunities and challenges for biostatisticians involved in DSMB processes.
This interactive panel will bring together thought leaders from industry and academia to examine how DSMBs must adapt to meet the demands of modern clinical research. Panelists will explore key topics including adaptive and platform trial designs, evolving governance models, and the imperative to enhance efficiency of decision-making through automation and AI-supported workflows
The Panelists:
- Corsee Sanders, Ph.D. - A global expert on DSMB governance, Dr. Sanders led Development Operations at Juno Therapeutics and served as Global Head of Biometrics and Clinical Operations at Roche/Genentech, where she chaired the DSMB Governance Committee. She currently serves on the boards of several biotech companies and is a trustee of the Fred Hutchinson Cancer Research Center.
- Professor Alex Kaizer. - Associate Professor of Biostatistics and Informatics at the University of Colorado Anschutz Medical Campus and faculty member in the Center for Innovative Design and Analysis. He specializes in Bayesian methods and adaptive clinical trials, and has served extensively as both a DSMB statistician and chair.
- Rick Landin. Ph.D. - President and CEO of Telperian, a software start-up company pioneering AI/ML-driven solutions to improve DSMB workflows, automate data review processes, and enhance decision support. With over 25 years in the pharmaceutical industry—including leadership roles at Eli Lilly, Biogen, and Neurocrine—Dr. Landin has advanced novel methodologies in statistics and machine learning for clinical trials, and has overseen successful regulatory submissions across a wide range of therapeutic areas.
The panel will be moderated by Dr. Julia Varshavsky, the CEO of OccamPoint, a consulting consortium of experts specializing in clinical development strategies for life sciences and digital health innovators. During her career as a biopharmaceutical statistician, Dr. Varshavsky has represented sponsors in DSMBs, advisory boards, and NIH settings, and now works with emerging life science ventures to integrate AI, data strategy, and scalable development models.
Audience Engagement
Attendees will have the opportunity to pose questions, share perspectives, and participate in a dialogue focused on how DSMBs can evolve to support faster, safer, and more intelligent clinical development.
Intended For
- Clinical trial statisticians and data scientists
- DSMB members, governance stakeholders, and support staff
- Clinical operations, safety, and medical monitoring professionals
- AI and digital health innovators exploring oversight and analytics
- CROs, sponsors, and regulatory strategists involved in data review
- Decision-makers shaping the future of decentralized and adaptive trials